SGEN [NASD]
Seagen Inc.
Index- P/E- EPS (ttm)-3.46 Insider Own0.30% Shs Outstand184.79M Perf Week-3.03%
Market Cap25.89B Forward P/E- EPS next Y-2.48 Insider Trans-14.71% Shs Float183.63M Perf Month-0.12%
Income-636.80M PEG- EPS next Q-1.03 Inst Own89.30% Short Float / Ratio1.63% / 3.20 Perf Quarter6.21%
Sales1.86B P/S13.89 EPS this Y-210.10% Inst Trans-2.10% Short Interest3.00M Perf Half Y-22.79%
Book/sh15.27 P/B9.04 EPS next Y30.40% ROA-17.50% Target Price162.57 Perf Year0.52%
Cash/sh9.40 P/C14.68 EPS next 5Y- ROE-21.60% 52W Range105.43 - 183.00 Perf YTD5.63%
Dividend- P/FCF- EPS past 5Y-30.10% ROI-22.20% 52W High-25.83% Beta0.59
Dividend %- Quick Ratio3.30 Sales past 5Y30.40% Gross Margin79.20% 52W Low28.75% ATR3.71
Employees2675 Current Ratio3.80 Sales Q/Q20.30% Oper. Margin-33.80% RSI (14)52.38 Volatility2.52% 2.90%
OptionableYes Debt/Eq0.00 EPS Q/Q35.90% Profit Margin-34.20% Rel Volume0.52 Prev Close138.00
ShortableYes LT Debt/Eq0.00 EarningsFeb 15 AMC Payout- Avg Volume938.08K Price135.74
Recom2.10 SMA200.52% SMA504.47% SMA200-5.77% Volume93,429 Change-1.64%
Feb-06-23Downgrade SVB Securities Outperform → Market Perform $162 → $141
Nov-21-22Initiated Truist Hold $135
Oct-11-22Upgrade BMO Capital Markets Market Perform → Outperform $177 → $178
Jun-29-22Initiated Raymond James Outperform $220
Jun-24-22Initiated BMO Capital Markets Market Perform $169
Feb-10-22Reiterated Wolfe Research Peer Perform $195 → $146
Feb-10-22Reiterated SVB Leerink Outperform $179 → $155
Feb-10-22Reiterated RBC Capital Mkts Sector Perform $154 → $132
Feb-10-22Reiterated Piper Sandler Neutral $165 → $150
Feb-10-22Reiterated Needham Buy $200 → $180
Show Previous Ratings
Jan-19-23 02:21PM
08:00AM
Dec-28-22 09:20AM
Dec-20-22 08:00AM
06:45AM
06:45AM Loading…
06:45AM
Dec-12-22 10:00AM
Dec-07-22 02:22PM
Dec-01-22 08:30AM
Nov-17-22 05:41AM
Nov-11-22 12:25AM
Nov-10-22 01:12PM
09:00AM
07:05AM
07:00AM
05:25PM Loading…
Oct-27-22 05:25PM
04:02PM
Oct-25-22 10:02AM
Oct-19-22 11:14AM
Oct-07-22 03:24AM
Oct-06-22 08:00AM
Sep-27-22 08:00AM
Sep-26-22 08:00AM
Sep-19-22 08:00AM
Sep-12-22 08:55AM
08:55AM
Sep-07-22 06:05PM
08:00AM
Aug-26-22 04:31PM
Aug-24-22 09:03AM
05:18PM Loading…
Aug-15-22 05:18PM
08:19AM
Aug-12-22 01:14PM
Aug-03-22 05:47PM
Jul-28-22 05:15PM
04:50PM
04:02PM
12:28PM
12:14PM
Jul-26-22 10:53AM
10:01AM
07:30AM
04:00AM
04:00AM
Jul-18-22 10:16AM
Jul-15-22 05:30PM
Jul-13-22 09:55AM
Jul-12-22 09:56AM
Jul-11-22 10:59AM
Jul-08-22 08:00AM
Jul-07-22 10:21PM
04:45PM
03:41PM
02:24PM
09:50AM
05:19AM
Jul-06-22 10:25AM
Jul-02-22 06:35AM
Jul-01-22 09:07AM
Jun-30-22 12:00PM
Jun-21-22 01:25PM
Jun-20-22 08:43AM
Jun-18-22 08:56AM
Jun-17-22 11:22AM
Jun-06-22 11:00AM
11:00AM
Jun-03-22 03:12PM
11:31AM
Jun-01-22 11:50AM
May-26-22 05:25PM
May-23-22 08:00AM
May-16-22 02:02PM
06:00AM
May-12-22 10:57AM
May-09-22 04:33PM
04:08PM
06:00AM
Apr-28-22 05:45PM
04:02PM
08:00AM
Apr-22-22 12:14AM
Apr-21-22 03:01PM
Apr-20-22 09:00AM
Apr-13-22 11:45AM
11:45AM
Apr-08-22 03:23PM
01:19PM
Apr-07-22 08:00AM
Mar-16-22 06:30AM
Mar-11-22 11:30AM
Mar-01-22 08:00AM
Feb-28-22 08:00AM
08:00AM
Feb-24-22 10:00AM
10:00AM
Feb-16-22 05:20AM
Feb-14-22 05:00PM
05:00PM
Feb-09-22 05:15PM
04:02PM
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DANSEY ROGER DPresident, R&D & CMOFeb 02Sale138.52783108,46196,853Feb 03 08:01 PM
LIU JEAN IChief Legal OfficerJan 24Option Exercise39.155,000195,75090,113Jan 26 07:39 PM
DANSEY ROGER DPresident, R&D & CMOJan 24Option Exercise72.6410,000726,400107,539Jan 26 07:41 PM
DANSEY ROGER DPresident, R&D & CMOJan 24Sale135.0010,0001,350,00097,539Jan 26 07:41 PM
LIU JEAN IChief Legal OfficerJan 24Sale135.035,000675,13485,113Jan 26 07:39 PM
LIU JEAN IChief Legal OfficerJan 17Sale130.7157875,54885,113Jan 19 07:16 PM
LIU JEAN IChief Legal OfficerJan 05Option Exercise39.154,525177,15490,216Jan 06 07:08 PM
DANSEY ROGER DPresident R&D & CMOJan 05Option Exercise72.647,500544,800105,039Jan 06 07:10 PM
DANSEY ROGER DPresident R&D & CMOJan 05Sale135.007,5001,012,50097,539Jan 06 07:10 PM
LIU JEAN IChief Legal OfficerJan 05Sale135.004,525610,87585,691Jan 06 07:08 PM
LIU JEAN IChief Legal OfficerJan 04Option Exercise39.1547518,59686,166Jan 06 07:08 PM
DANSEY ROGER DPresident R&D & CMOJan 04Option Exercise72.642,500181,600100,039Jan 06 07:10 PM
DANSEY ROGER DPresident R&D & CMOJan 04Sale135.002,500337,50097,539Jan 06 07:10 PM
LIU JEAN IChief Legal OfficerJan 04Sale135.0047564,12585,691Jan 06 07:08 PM
ROMP CHARLES REVP, Commercial U.S.Dec 20Sale127.631,129144,09458,475Dec 21 06:48 PM
DANSEY ROGER DPresident, Research and DeveloDec 14Option Exercise77.1610,000771,628106,942Dec 16 07:42 PM
DANSEY ROGER DPresident, Research and DeveloDec 14Sale135.0010,0001,350,00097,539Dec 16 07:42 PM
Simonian Nancy ADirectorDec 12Option Exercise36.708,750321,12562,753Dec 14 05:49 PM
LIU JEAN IChief Legal OfficerNov 17Option Exercise34.208,333284,98994,024Nov 18 07:53 PM
LIU JEAN IChief Legal OfficerNov 17Sale131.058,3331,092,05685,691Nov 18 07:53 PM
LIU JEAN IChief Legal OfficerNov 14Option Exercise76.861,30199,99585,691Nov 16 06:22 PM
GRYSKA DAVID WDirectorNov 11Sale129.107,500968,22040,253Nov 15 05:46 PM
DANSEY ROGER DInterim CEO & CMOOct 17Option Exercise74.5410,000745,421102,146Oct 19 07:17 PM
DANSEY ROGER DInterim CEO & CMOOct 17Sale135.0010,0001,350,00097,539Oct 19 07:17 PM
SIMPSON TODD EChief Financial OfficerAug 31Sale154.414,186646,379137,185Sep 01 06:09 PM
ROMP CHARLES REVP, CommercialAug 31Sale154.411,133174,95259,604Sep 01 06:06 PM
HIMES VAUGHN BChief Technical OfficerAug 31Sale154.413,584553,42267,183Sep 01 06:07 PM
LIU JEAN IChief Legal OfficerAug 31Sale154.413,648563,30484,390Sep 01 06:03 PM
DANSEY ROGER DInterim CEO & CMOAug 31Sale154.415,019775,00697,539Sep 01 06:03 PM
SIMPSON TODD EChief Financial OfficerAug 16Sale170.221,967334,813141,371Aug 17 09:19 PM
ROMP CHARLES REVP, CommercialAug 16Sale170.221,765300,43060,737Aug 17 09:16 PM
LIU JEAN IChief Legal OfficerAug 16Sale170.221,639278,98388,038Aug 17 09:14 PM
HIMES VAUGHN BChief Technical OfficerAug 16Sale170.221,527259,91870,767Aug 17 09:13 PM
DANSEY ROGER DInterim CEO & CMOAug 16Sale170.224,254724,095102,558Aug 17 09:12 PM
ROMP CHARLES REVP, CommercialJul 05Sale179.46712127,77648,771Jul 07 06:50 PM
DANSEY ROGER DChief Medical OfficerJun 28Option Exercise65.1119,7441,285,53294,336Jun 30 06:02 PM
DANSEY ROGER DChief Medical OfficerJun 28Sale180.0034,6356,234,30062,084Jun 30 06:02 PM
HIMES VAUGHN BChief Technical OfficerJun 17Option Exercise41.041,13446,53960,198Jun 22 07:03 PM
HIMES VAUGHN BChief Technical OfficerJun 17Sale160.001,134181,440119,471Jun 22 07:03 PM
HIMES VAUGHN BChief Technical OfficerMay 24Option Exercise26.1010,866283,60367,359May 26 06:07 PM
HIMES VAUGHN BChief Technical OfficerMay 24Sale136.7910,8661,486,37759,064May 26 06:07 PM
ROMP CHARLES REVP, CommercialMay 16Sale134.2133344,69149,483May 18 07:34 PM
SIEGALL CLAY BPresident & CEOMay 12Option Exercise26.1017,043444,822676,653May 13 07:13 PM
SIEGALL CLAY BPresident & CEOMay 12Sale125.6917,0432,142,117666,060May 13 07:13 PM
DANSEY ROGER DChief Medical OfficerApr 21Sale144.1565293,98676,975Apr 22 08:27 PM
SIEGALL CLAY BPresident & CEOApr 20Sale144.321,885272,041666,060Apr 22 08:34 PM
SIMPSON TODD EChief Financial OfficerApr 20Sale144.3256781,829127,891Apr 22 08:32 PM
LIU JEAN IChief Legal OfficerApr 20Sale144.3240157,87275,946Apr 22 08:31 PM
ROMP CHARLES REVP, CommercialApr 20Sale144.3231946,03849,816Apr 22 08:30 PM
HIMES VAUGHN BChief Technical OfficerApr 20Sale144.3257482,83959,064Apr 22 08:29 PM
DANSEY ROGER DChief Medical OfficerApr 20Sale144.32787113,57977,627Apr 22 08:27 PM
GRYSKA DAVID WDirectorApr 19Option Exercise20.064,00080,24048,044Apr 21 06:37 PM
GRYSKA DAVID WDirectorApr 19Sale143.954,000575,78346,250Apr 21 06:37 PM
SIEGALL CLAY BPresident and CEOApr 07Option Exercise26.1017,043444,822672,637Apr 08 09:41 PM
SIEGALL CLAY BPresident and CEOApr 07Sale154.2317,0432,628,610667,945Apr 08 09:41 PM
BAKER BROS. ADVISORS LPDirectorMar 08Option Exercise20.0635,000702,10042,965,004Mar 10 04:39 PM
SIEGALL CLAY BPresident & CEOMar 07Option Exercise26.1017,043444,822674,588Mar 09 07:42 PM
SIEGALL CLAY BPresident & CEOMar 07Sale134.3517,0432,289,655667,945Mar 09 07:42 PM
HIMES VAUGHN BChief Technical OfficerMar 03Option Exercise26.1012,000313,20070,343Mar 04 07:24 PM
HIMES VAUGHN BChief Technical OfficerMar 03Sale127.0512,0001,524,55859,500Mar 04 07:24 PM
Simonian Nancy ADirectorMar 02Option Exercise20.0425,000501,00052,500Mar 04 05:09 PM
GRYSKA DAVID WDirectorFeb 07Option Exercise20.064,50090,27048,621Feb 09 06:58 PM
SIEGALL CLAY BPresident & CEOFeb 07Option Exercise26.1017,043444,822676,930Feb 09 07:02 PM
SIEGALL CLAY BPresident & CEOFeb 07Sale139.9717,0432,385,566667,945Feb 09 07:02 PM
GRYSKA DAVID WDirectorFeb 07Sale138.764,500624,44146,250Feb 09 06:58 PM